SYMPOSIA

Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org
Poster Presentations
genomic diagnostics to apply this information into practice in medical clinics. In this perspective, our goal is to design a diagnostic assay
for the Prediction of Drug Response for Schizophrenia to especially guide the initial selection of antipsychotics based on the individual
genomic information of the patients.
Initially a literature search has been done to identify previously described SNPs associated with schizophrenia that are known to effect
the response to antipsychotics or predict the side effects of antipsychotic drugs. Twenty-two SNPs are identified, that map to 8 genes.
Next, we have applied the novel AHP based SNP prioritization approach implemented in the METU-SNP software for GWAS to the SNP
Genotyping data for the European American population (from dbGAP database), with 1351 patients and 1378 controls genotyped for
over 729454 SNPs. The 22 SNPs selected based on the literature were cross-checked with the results of GWAS and prioritized in order to
finalize the pharmacogenomics of the SNP (p-SNP) panel for schizophrenia and to determine the order of SNPs to be targeted in the assay
development process. The pyro-sequencing approach was used during the development of the assay to determine the genotypes of the
patients for the SNPs selected for the panel. After the next phase of our project, which is the development and optimization of primer
sets, is completed a validation study will be designed in collaboration with psychiatric clinics for the described p-SNP kit panel and the
supporting software that is in-line, for development of easy translation of the genotyping results to support the clinical decision of the
choice of therapy.
Application of personalized medicine approaches and utilizing genomic diagnostic assays as presented here will eliminate or decrease
the number of trials-and-errors in selecting sthe right treatment and dosage for particuler patient, and will also minimize emergency
visits due to side effects of the drugs. In addition, the prescription of the right medicine and treatment plan at the initial diagnosis
of schizophrenia will increase trust between healthcare professionals and patients, which in return is expected to provide higher
cooperation and adherance rates of patients to their treatment. Overall the personalized medicine approach is expected to decrease the
cost of healthcare in psychiatry and other disciplines, while offering higher quality healthcare.
Key words: Pharmacogenomics, personalized medicine, translational medicine, genomic diagnostics, medical decision support systems, GWAS,
SNP genotyping, METU-SNP, schizophrenia
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S156-7
[PP-060] Ref. No: 200
Basal ganglial hemorrhage induced mania
Barış Yılbaş 1 , Murat Gönen 2
1Department of Psychiatry, Elbistan State Hospital, Elbistan-K.Maraş, Turkey
2Department of Neurology, Elbistan State Hospital, Elbistan-K.Maraş, Turkey
E-mail: barisyilbas@mynet.com
Neuroimaging studies on mood disorders concentrate on the limbic system, especially on the hippocampus and amygdala. Accumulating
evidence suggests an association between abnormalities of the basal ganglia and mood disorders. We present a case of mania following
basal ganglial hemorrhage.
A 30-year old male, with no history of bipolar disorder, was admitted to the emergency room with complaints of euphoria and decreased
need for sleep. During psychiatric assessment, he exhibited grandiosity, psychomotor activation, irritability, and flight of ideas. The
patient,whose cranial MRI showed hemorrhage in the basal ganglia, was hospitalized with a diagnosis of mood disorder due to a general
medical condition. Lorazepam 5mg/day and olanzapine 10mg/day was started. On the tenth day of treatment his episode ended.
The basal ganglia are interconnected with the limbic system and prefrontal cortex and therefore are implicated in bipolar disorder.
Key words: Basal ganglia hemorrhage, mania
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S157
S157